The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research

Raúl M. Luque, Alejandro Ibáñez-Costa, Laura Sánchez-Tejada, Esther Rivero-Cortés, Mercedes Robledo, Ainara Madrazo-Atutxa, Mireia Mora, Clara V. Álvarez, Tomás Lucas-Morante, Cristina Álvarez-Escolá, Carmen Fajardo, Luis Castaño, Sonia Gaztambide, Eva Venegas-Moreno, Alfonso Soto-Moreno, María Ángeles Gálvez, Javier Salvador, Elena Valassi, Susan M. Webb, Antonio PicóManel Puig-Domingo, Montserrat Gilabert, Ignacio Bernabéu, Mónica Marazuela, Alfonso Leal-Cerro, Justo P. Castaño

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

© 2016 SEEN Pituitary adenomas are uncommon, difficult to diagnose tumors whose heterogeneity and low incidence complicate large-scale studies. The Molecular Registry of Pituitary Adenomas (REMAH) was promoted by the Andalusian Society of Endocrinology and Nutrition (SAEN) in 2008 as a cooperative clinical-basic multicenter strategy aimed at improving diagnosis and treatment of pituitary adenomas by combining clinical, pathological, and molecular information. In 2010, the Spanish Society of Endocrinology and Nutrition (SEEN) extended this project to national level and established 6 nodes with common protocols and methods for sample and clinical data collection, molecular analysis, and data recording in a common registry (www.remahnacional.com). The registry combines clinical data with molecular phenotyping of the resected pituitary adenoma using quantitative real-time PCR of expression of 26 genes: Pituitary hormones (GH-PRL-LH-FSH-PRL-ACTH-CGA), receptors (somatostatin, dopamine, GHRH, GnRH, CRH, arginine-vasopressin, ghrelin), other markers (Ki67, PTTG1), and control genes. Until 2015, molecular information has been collected from 704 adenomas, out of 1179 patients registered. This strategy allows for comparative and relational analysis between the molecular profile of the different types of adenoma and the clinical phenotype of patients, which may provide a better understanding of the condition and potentially help in treatment selection. The REMAH is therefore a unique multicenter, interdisciplinary network founded on a shared database that provides a far-reaching translational approach for management of pituitary adenomas, and paves the way for the conduct of combined clinical-basic innovative studies on large patient samples.
Original languageEnglish
Pages (from-to)274-284
JournalEndocrinologia y Nutricion
Volume63
Issue number6
DOIs
Publication statusPublished - 1 Jun 2016

Keywords

  • Acromegaly
  • Cushing
  • Multicenter study
  • Pituitary adenoma
  • Tumor

Fingerprint Dive into the research topics of 'The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research'. Together they form a unique fingerprint.

  • Cite this

    Luque, R. M., Ibáñez-Costa, A., Sánchez-Tejada, L., Rivero-Cortés, E., Robledo, M., Madrazo-Atutxa, A., Mora, M., Álvarez, C. V., Lucas-Morante, T., Álvarez-Escolá, C., Fajardo, C., Castaño, L., Gaztambide, S., Venegas-Moreno, E., Soto-Moreno, A., Gálvez, M. Á., Salvador, J., Valassi, E., Webb, S. M., ... Castaño, J. P. (2016). The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research. Endocrinologia y Nutricion, 63(6), 274-284. https://doi.org/10.1016/j.endonu.2016.03.001